Source of material
The bridged diamine 12-(3,4-dimethoxyphenyl)-4,5-dimethoxy-11,14-diaza-tricyclo[7.4.1.0 2 ' 7 ]tetradeca-2(7),3,5-trien-10-one was obtained in few steps from a protected dipeptide, which had in turn been derived from L-dopa and DL-/?-dopa [1] , 50 mg (125 μπιοί) of 12-(3,4-dimethoxyphenyl)-4,5-dimethoxy-ll,14-diaza-tricyclo[7.4.1.0 2 ' 7 ]tetradeca-2(7),3,5-trien-10-one a diamine incorporating a tetrahydroquinoline and an 1,4-diazepane ring [2] , and 36 mg (62.5 μπιοί) of the chloro-bridged complex (Et 3 P)2Pd 2 Cl2(a-Cl)2 were stirred in CHCI3/CH3OH (1:1 v/v)for 12 h. The yellow solution was concentrated in vacuo and the residue overlayered with n-hexane. Yellow needles of the title compound were obtained.
Discussion
The crystal structure of the racemic palladium complex proves the relative configuration of the two enantiomers of the diamine ligand as (15,35,10Ä)/(1Ä,3Ä,10S). The calculated [1] conformation of the ligand is very similar to that in the title complex. The nitrogen atom of the tetrahydroisoquinoline ring [3] is coordinated to palladium, d(Pd-N) = 2.208(3) A, ZN-Pd-P = 173.68(7)°, and the phosphane ligand is situated trans to the Ndonor. Thus, the title compound is another example in a large series of palladium and platinum complexes with trans-RiP-M-Ndonor structure, which is in perfect accordance with DFT calculations on the thermodynamic stability of such planar complexes [4] . In the crystal structure a methanol molecule is attached to the complex molecule via an hydrogen bridge to the lactam Ο atom. 
